Novel Approaches to Treatment of Hepatocellular Carcinoma and Hepatic Metastases Using Thermal Ablation and Thermosensitive Liposomes

Surgical Oncology Clinics of North America

Volumn 22, Issue 3, 2013, Pages 545-561

  Dewhirst, Mark W ^a,b   Landon, Chelsea D ^a   Hofmann, Christina L ^b   Stauffer, Paul R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Duke University   (United States)

Author keywords

Hepatocellular carcinoma; Thermal ablation; Thermosensitive liposomes

Indexed keywords

DOXORUBICIN; LIPOSOME;

ABLATION THERAPY; ANTINEOPLASTIC ACTIVITY; COMPARATIVE EFFECTIVENESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; DRUG SAFETY; DRUG STABILITY; DRUG TOLERABILITY; DRUG UPTAKE; HUMAN; HYPERTHERMIC THERAPY; LIPOSOMAL DELIVERY; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER NECROSIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHUMAN; RADIOFREQUENCY ABLATION; REVIEW; SARCOMA; TEMPERATURE DEPENDENCE;

CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; HUMANS; HYPERTHERMIA, INDUCED; LIPOSOMES; LIVER NEOPLASMS; PROGNOSIS;

EID: 84876869073     PISSN: 10553207     EISSN: 15585042     Source Type: Journal    
DOI: 10.1016/j.soc.2013.02.009     Document Type: Review

References (83)

1. Poon R., Borys N. Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer. Expert Opin Pharmacother 2009, 10(2):333-343.
2. Lencioni R., Crocetti L., Cioni D., et al. Percutaneous radiofrequency ablation of hepatic colorectal metastases-technique, indications, results, and new promises. Invest Radiol 2004, 39(11):689-697.
3. Solbiati L., Livraghi T., Goldberg S.N., et al. Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 2001, 221(1):159-166.
4. Stauffer P.R., Diederich C.J., Seegenschmiedt M.H. Interstitial heating technologies. Thermoradiotherapy and thermochemotherapy: volume 1, biology, physiology and physics 1995, 279-320. Springer-Verlag, Berlin, New York. M.H. Seegenschmiedt, P. Fessenden, C.C. Vernon (Eds.).
5. Stauffer P.R., Goldberg S.N. Introduction: thermal ablation therapy. Int J Hyperthermia 2004, 20(7):671-677.
6. Schirmang T.C., Dupuy D.E. Image-guided thermal ablation of nonresectable hepatic tumors using the Cool-Tip radiofrequency ablation system. Expert Rev Med Devices 2007, 4(6):803-814.
7. Koda M., Tokunaga S., Matono T., et al. Comparison between different thickness umbrella-shaped expandable radiofrequency electrodes (SuperSlim and CoAccess): experimental and clinical study. Exp Ther Med 2011, 2(6):1215-1220.
8. Lencioni R., Crocetti L. Image-guided ablation for hepatocellular carcinoma. Recent Results Cancer Res 2013, 190:181-194.
9. Liu Y., Zheng Y., Li S., et al. Percutaneous microwave ablation of larger hepatocellular carcinoma. Clin Radiol 2013, 68(1):21-26.
10. Andreano A., Huang Y., Meloni M.F., et al. Microwaves create larger ablations than radiofrequency when controlled for power in ex vivo tissue. Med Phys 2010, 37(6):2967-2973.
11. Brace C.L. Radiofrequency and microwave ablation of the liver, lung, kidney, and bone: what are the differences?. Curr Probl Diagn Radiol 2009, 38(3):135-143.
12. Pacella C.M., Francica G., Di Costanzo G.G. Laser ablation for small hepatocellular carcinoma. Radiol Res Pract 2011, 2011:595627.
13. Francica G., Petrolati A., Di Stasio E., et al. Influence of ablative margin on local tumor progression and survival in patients with HCC
14. Vogl T.J., Jost A., Nour-Eldin N.A., et al. Repeated transarterial chemoembolisation using different chemotherapeutic drug combinations followed by MR-guided laser-induced thermotherapy in patients with liver metastases of colorectal carcinoma. Br J Cancer 2012, 106(7):1274-1279.
15. Cheung T.T., Chu F.S., Jenkins C.R., et al. Tolerance of high-intensity focused ultrasound ablation in patients with hepatocellular carcinoma. World J Surg 2012, 36(10):2420-2427.
16. Staruch R., Chopra R., Hynynen K. Localised drug release using MRI-controlled focused ultrasound hyperthermia. Int J Hyperthermia 2011, 27(2):156-171.
17. Wijlemans J.W., Bartels L.W., Deckers R., et al. Magnetic resonance-guided high-intensity focused ultrasound (MR-HIFU) ablation of liver tumours. Cancer Imaging 2012, 12(2):387-394.
18. Widmann G., Schullian P., Haidu M., et al. Stereotactic radiofrequency ablation (SRFA) of liver lesions: technique effectiveness, safety, and interoperator performance. Cardiovasc Intervent Radiol 2012, 35(3):570-580.
19. Hahn G.M., Strande D.P. Cytotoxic effects of hyperthermia and adriamycin on Chinese hamster cells. J Natl Cancer Inst 1976, 57(5):1063-1067.
20. Overgaard J. Combined adriamycin and hyperthermia treatment of a murine mammary carcinoma in vivo. Cancer Res 1976, 36(9 Pt 1):3077-3081.
21. Rotstein L.E., Daly J., Rozsa P. Systemic thermochemotherapy in a rat model. Can J Surg 1983, 26(2):113-116.
22. Haas G.P., Klugo R.C., Hetzel F.W., et al. The synergistic effect of hyperthermia and chemotherapy on murine transitional cell-carcinoma. J Urol 1984, 132(4):828-833.
23. Dahl O. Hyperthermic potentiation of doxorubicin and 4'-epi-doxorubicin in a transplantable neurogenic rat tumor (BT4A) in BD IX rats. Int J Radiat Oncol Biol Phys 1983, 9(2):203-207.
24. Mostafa E.M., Ganguli S., Faintuch S., et al. Optimal strategies for combining transcatheter arterial chemoembolization and radiofrequency ablation in rabbit VX2 hepatic tumors. J Vasc Interv Radiol 2008, 19(12):1740-1748.
25. Gabizon A., Peretz T., Sulkes A., et al. Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I study. Eur J Cancer Clin Oncol 1989, 25(12):1795-1803.
26. Safra T., Muggia F., Jeffers S., et al. Pegylated liposomal doxorubicin (Doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m(2). Ann Oncol 2000, 11(8):1029-1033.
27. Landon C.D., Park J.Y., Needham D., et al. Nanoscale drug delivery and dyperthermia: the materials design and preclinical and clinical testing of low temperature-sensitive liposomes used in combination with mild hyperthermia in the treatment of local cancer. Open Nanomed J 2011, 3:38-64.
28. Gregoriadis G. Engineering liposomes for drug delivery: progress and problems. Trends Biotechnol 1995, 13(12):527-537.
29. Li X., Hirsh D.J., Cabral-Lilly D., et al. Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient. Biochim Biophys Acta 1998, 1415(1):23-40.
30. Ahmed M., Liu Z., Lukyanov A.N., et al. Combination radiofrequency ablation with intratumoral liposomal doxorubicin: effect on drug accumulation and coagulation in multiple tissues and tumor types in animals. Radiology 2005, 235(2):469-477.
31. Ahmed M., Lukyanov A.N., Torchilin V., et al. Combined radiofrequency ablation and adjuvant liposomal chemotherapy: effect of chemotherapeutic agent, nanoparticle size, and circulation time. J Vasc Interv Radiol 2005, 16(10):1365-1371.
32. Ahmed M., Monsky W.E., Girnun G., et al. Radiofrequency thermal ablation sharply increases intratumoral liposomal doxorubicin accumulation and tumor coagulation. Cancer Res 2003, 63(19):6327-6333.
33. D'Ippolito G., Ahmed M., Girnun G.D., et al. Percutaneous tumor ablation: reduced tumor growth with combined radio-frequency ablation and liposomal doxorubicin in a rat breast tumor model. Radiology 2003, 228(1):112-118.
34. Goldberg S.N., Girnan G.D., Lukyanov A.N., et al. Percutaneous tumor ablation: increased necrosis with combined radio-frequency ablation and intravenous liposomal doxorubicin in a rat breast tumor model. Radiology 2002, 222(3):797-804.
35. Goldberg S.N., Kamel I.R., Kruskal J.B., et al. Radiofrequency ablation of hepatic tumors: increased tumor destruction with adjuvant liposomal doxorubicin therapy. Am J Roentgenol 2002, 179(1):93-101.
36. Solazzo S., Mertyna P., Peddi H., et al. RF ablation with adjuvant therapy: comparison of external beam radiation and liposomal doxorubicin on ablation efficacy in an animal tumor model. Int J Hyperthermia 2008, 24(7):560-567.
37. Ahmed M., Goldberg S.N. Combination radiofrequency thermal ablation and adjuvant IV liposomal doxorubicin increases tissue coagulation and intratumoural drug accumulation. Int J Hyperthermia 2004, 20(7):781-802.
38. Ahmed M., Moussa M., Goldberg S.N. Synergy in cancer treatment between liposomal chemotherapeutics and thermal ablation. Chem Phys Lipids 2012, 165(4):424-437.
39. Solazzo S.A., Ahmed M., Schor-Bardach R., et al. Liposomal doxorubicin increases radiofrequency ablation-induced tumor destruction by increasing cellular oxidative and nitrative stress and accelerating apoptotic pathways. Radiology 2010, 255(1):62-74.
40. Gasselhuber A., Dreher M.R., Negussie A., et al. Mathematical spatio-temporal model of drug delivery from low temperature sensitive liposomes during radiofrequency tumour ablation. Int J Hyperthermia 2010, 26(5):499-513.
41. Kong G., Dewhirst M.W. Hyperthermia and liposomes. Int J Hyperthermia 1999, 15(5):345-370.
42. Kong G., Anyarambhatla G., Petros W.P., et al. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res 2000, 60(24):6950-6957.
43. Needham D., Anyarambhatla G., Kong G., et al. A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res 2000, 60(5):1197-1201.
44. Koning G.A., Eggermont A.M., Lindner L.H., et al. Hyperthermia and thermosensitive liposomes for improved delivery of chemotherapeutic drugs to solid tumors. Pharm Res 2010, 27(8):1750-1754.
45. Weinstein J.N., Magin R.L., Yatvin M.B., et al. Liposomes and local hyperthermia: selective delivery of methotrexate to heated tumors. Science 1979, 204(4389):188-191.
46. Yatvin M.B., Weinstein J.N., Dennis W.H., et al. Design of liposomes for enhanced local release of drugs by hyperthermia. Science 1978, 202(4374):1290-1293.
47. Yatvin M.B., Muhlensiepen H., Porschen W., et al. Selective delivery of liposome-associated cis-dichlorodiammineplatinum(II) by heat and its influence on tumor drug uptake and growth. Cancer Res 1981, 41(5):1602-1607.
48. Yatvin M.B., Cree T.C., Tegmo-Larsson I.M., et al. Liposomes as drug carriers in cancer therapy: hyperthermia and pH sensitivity as modalities for targeting. Strahlentherapie 1984, 160(12):732-740.
49. Gaber M.H., Hong K., Huang S.K., et al. Thermosensitive sterically stabilized liposomes: formulation and in vitro studies on mechanism of doxorubicin release by bovine serum and human plasma. Pharm Res 1995, 12(10):1407-1416.
50. Papahadjopoulos D., Allen T.M., Gabizon A., et al. Sterically stabilized liposomes-improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A 1991, 88(24):11460-11464.
51. Gaber M.H., Wu N.Z., Hong K., et al. Thermosensitive liposomes: extravasation and release of contents in tumor microvascular networks. Int J Radiat Oncol Biol Phys 1996, 36(5):1177-1187.
52. Dewhirst M.W., Vujaskovic Z., Jones E., et al. Re-setting the biologic rationale for thermal therapy. Int J Hyperthermia 2005, 21(8):779-790.
53. Lindner L.H., Eichhorn M.E., Eibl H., et al. Novel temperature-sensitive liposomes with prolonged circulation time. Clin Cancer Res 2004, 10(6):2168-2178.
54. Hossann M., Wiggenhorn M., Schwerdt A., et al. In vitro stability and content release properties of phosphatidylglyceroglycerol containing thermosensitive liposomes. Biochim Biophys Acta 2007, 1768(10):2491-2499.
55. Hossann M., Syunyaeva Z., Schmidt R., et al. Proteins and cholesterol lipid vesicles are mediators of drug release from thermosensitive liposomes. J Control Release 2012, 162(2):400-406.
56. Dicheva B.M., Hagen T.L., Li L., et al. Cationic thermosensitive liposomes: a novel dual targeted heat-triggered drug delivery approach for endothelial and tumor cells. Nano Lett 2012, [Epub ahead of print].
57. Manzoor A.A., Lindner L.H., Landon C.D., et al. Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors. Cancer Res 2012, 72(21):5566-5575.
58. Kono K. Thermosensitive polymer-modified liposomes. Adv Drug Deliv Rev 2001, 53(3):307-319.
59. Ruel-Gariepy E., Leclair G., Hildgen P., et al. Thermosensitive chitosan-based hydrogel containing liposomes for the delivery of hydrophilic molecules. J Control Release 2002, 82(2-3):373-383.
60. Kono K., Nakai R., Morimoto K., et al. Thermosensitive polymer-modified liposomes that release contents around physiological temperature. Biochim Biophys Acta 1999, 1416(1-2):239-250.
61. Pradhan P., Giri J., Rieken F., et al. Targeted temperature sensitive magnetic liposomes for thermo-chemotherapy. J Control Release 2010, 142(1):108-121.
62. Unezaki S., Maruyama K., Takahashi N., et al. Enhanced delivery and antitumor-activity of doxorubicin using long-circulating thermosensitive liposomes containing amphipathic polyethylene-glycol in combination with local hyperthermia. Pharm Res 1994, 11(8):1180-1185.
63. Yarmolenko P.S., Zhao Y., Landon C., et al. Comparative effects of thermosensitive doxorubicin-containing liposomes and hyperthermia in human and murine tumours. Int J Hyperthermia 2010, 26(5):485-498.
64. Palmer G.M., Boruta R.J., Viglianti B.L., et al. Non-invasive monitoring of intra-tumor drug concentration and therapeutic response using optical spectroscopy. J Control Release 2010, 142(3):457-464.
65. Jung E.U., Yoon J.H., Lee Y.J., et al. Hypoxia and retinoic acid-inducible NDRG1 expression is responsible for doxorubicin and retinoic acid resistance in hepatocellular carcinoma cells. Cancer Lett 2010, 298(1):9-15.
66. Ponce A.M., Viglianti B.L., Yu D., et al. Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects. J Natl Cancer Inst 2007, 99(1):53-63.
67. Viglianti B.L., Ponce A.M., Michelich C.R., et al. Chemodosimetry of in vivo tumor liposomal drug concentration using MRI. Magn Reson Med 2006, 56(5):1011-1018.
68. Negussie A.H., Yarmolenko P.S., Partanen A., et al. Formulation and characterisation of magnetic resonance imageable thermally sensitive liposomes for use with magnetic resonance-guided high intensity focused ultrasound. Int J Hyperthermia 2011, 27(2):140-155.
69. de Smet M., Heijman E., Langereis S., et al. Magnetic resonance imaging of high intensity focused ultrasound mediated drug delivery from temperature-sensitive liposomes: an in vivo proof-of-concept study. J Control Release 2011, 150(1):102-110.
70. Peller M., Schwerdt A., Hossann M., et al. MR characterization of mild hyperthermia-induced gadodiamide release from thermosensitive liposomes in solid tumors. Invest Radiol 2008, 43(12):877-892.
71. Ranjan A., Jacobs G.C., Woods D.L., et al. Image-guided drug delivery with magnetic resonance guided high intensity focused ultrasound and temperature sensitive liposomes in a rabbit Vx2 tumor model. J Control Release 2012, 158(3):487-494.
72. Chen Q., Tong S., Dewhirst M.W., et al. Targeting tumor microvessels using doxorubicin encapsulated in a novel thermosensitive liposome. Mol Cancer Ther 2004, 3(10):1311-1317.
73. Hauck M.L., LaRue S.M., Petros W.P., et al. Phase I trial of doxorubicin-containing low temperature sensitive liposomes in spontaneous canine tumors. Clin Cancer Res 2006, 12(13):4004-4010.
74. Poon R.T., Borys N. Lyso-thermosensitive liposomal doxorubicin: an adjuvant to increase the cure rate of radiofrequency ablation in liver cancer. Future Oncol 2011, 7(8):937-945.
75. Wood B.J., Poon R.T., Locklin J.K., et al. Phase I study of heat-deployed liposomal doxorubicin during radiofrequency ablation for hepatic malignancies. J Vasc Interv Radiol 2012, 23(2):248-255.e7.
76. Celsion Phase 3 study of ThermoDox with radiofrequency ablation (RFA) in treatment of hepatocellular carcinoma (HCC) 2011, National Library of Medicine (US), Bethesda (MD), Available at:, [Internet] [Accessed June 15, 2012]. http://ClinicalTrials.gov.
77. Celsion Phase 1/2 study of ThermoDox with approved hyperthermia in treatment of breast cancer recurrence at the chest wall (DIGNITY) 2012, National Library of Medicine (US), Bethesda (MD), Available at:, [Internet] [Accessed June 15, 2012]. http://ClinicalTrials.gov.
78. Jones E.L., Samulski T.V., Dewhirst M.W., et al. A pilot Phase II trial of concurrent radiotherapy, chemotherapy, and hyperthermia for locally advanced cervical carcinoma. Cancer 2003, 98(2):277-282.
79. Rau B., Wust P., Hohenberger P., et al. Preoperative hyperthermia combined with radiochemotherapy in locally advanced rectal cancer: a phase II clinical trial. Ann Surg 1998, 227(3):380-389.
80. de Wit R., van der Zee J., van der Burg M.E., et al. A phase I/II study of combined weekly systemic cisplatin and locoregional hyperthermia in patients with previously irradiated recurrent carcinoma of the uterine cervix. Br J Cancer 1999, 80(9):1387-1391.
81. van der Zee J., Gonzalez Gonzalez D., van Rhoon G.C., et al. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group. Lancet 2000, 355(9210):1119-1125.
82. Issels R.D., Lindner L.H., Verweij J., et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol 2010, 11(6):561-570.
83. Overgaard J., Gonzalez Gonzalez D., Hulshof M.C., et al. Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology. Lancet 1995, 345(8949):540-543.